The US has also ordered 3.1 million doses of molnupiravir for around $2.2 billion. Merck – which is developing the drug with Ridgeback Biotherapeutics – is one step ahead for a regulatory ...

Merck MRK reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding ...

Twenty-seven drug makers have signed onto a deal to manufacture a generic version of molnupiravir, Merck's oral antiviral for the treatment of COVID-19.The deal will allow affordable access to the ...

The FDA will scrutinize company data on the safety and effectiveness of the drug, molnupiravir, before rendering a decision. Merck and its partner Ridgeback Biotherapeutic said they specifically ...

The federal regulator said it continues to receive data "as new information becomes available" from pharmaceutical company Merck on their drug molnupiravir, considered the first pill to ...

Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...